Supplementary Figure S10 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors

Le résumé fourni par la source

Supplementary Figure S10. HER2-Directed Therapy Response Modifying Alterations In Select Cancers (Related To Figure 4) Co-occurrence of alterations that have been reported to impact response to HER2-directed therapies (mAB, TKI, ADC) in tumors with ERBB2 amplification or ERBB2 activating mutations including TP53 MUT, PIK3CA MUT, CCNE1 AMP, RB1 MUT/DEL, PTEN MUT/DEL, ERBB3 AMP/MUT, EGFR MUT, MET AMP/Ex14 MUT, and IGF1R AMP. Patients with multiple ERBB2 alteration types (e.g., AMP + MUT) were excluded from the analysis. ADC, Antibody-Drug Conjugate; AMP, Amplification; mAB, Monoclonal Antibodies; MUT, Mutation (SNV, Indel); TKI, Tyrosine Kinase Inhibitor.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.